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Abstract
Background: In sub-Saharan Africa, there is a dearth of published literature on extrapulmonary tuberculosis (EPTB).
Objective: To describe demographic, diagnostic and HIV-status characteristics of patients with EPTB in Be´nin, their
treatment outcomes, and among those who completed their treatment in the Centre National Hospitalier de Pneumo-
Phtisiologie (CNHP-P), the proportion whose bodyweight increased during treatment.
Material and Findings: This was a retrospective cohort study with comparisons made between EPTB and new smear-
positive pulmonary tuberculosis (NPTB) patients diagnosed in the country from January to December 2011. There were 383
EPTB patients (9% of all TB cases) with a mean age of 35 years, male/female ratio of 1.3 and important regional variation.
There were significantly more females (p = 0.001), children ,15years (p,0.001) and HIV-positive patients (p = 0.005) with
EPTB compared with NPTB. Pleural effusion, spinal and lymph node tuberculosis accounted for 66% of all EPTB. Children ,
15 years represented 16% of cases, with lymph node disease being most common among them (p,0.001). Of 130 EPTB
patients registered in CNHP-P, 7% had a confirmed bacteriological/histological diagnosis. There were 331 (86%) patients
who successfully completed treatment. More patients with EPTB were lost-to-follow-up compared with NPTB (p,0.001)
with all these patients from one region. The best treatment completion rates were in children ,15 years (OR:3.5, 95%CI:1.0–
14.8) while patients with pleural effusion and ascites had the worst outcomes. Of 72 HIV-coinfected patients, 88% were on
antiretroviral therapy (ART). HIV-positive status was associated with poor outcomes while those on ART fared better. In the
CNHP-P, more than 80% who completed their treatment showed an increase in bodyweight and this was more evident in
HIV-positive compared with HIV-negative patients (p = 0.03).
Conclusion: Patients with EPTB generally do well in Be´nin, although the TB Programme would benefit through more
attention to accurate diagnosis and earlier start of ART in HIV-infected patients.
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Introduction
Patients with extrapulmonary tuberculosis (EPTB), i.e., tuber-
culosis (TB) without associated lung involvement, usually receive
less priority in national TB Programmes. However, in many
countries, their numbers remain either stable or are increasing
while numbers of patients with pulmonary disease are decreasing
[1]. In populations with a low prevalence of HIV infection, these
patients usually represent 15% to 20% of all TB cases. However,
this proportion is thought to be higher in populations with a high
prevalence of HIV infection [2], the latter mostly occurring in sub-
Saharan Africa.
Confirmation of the diagnosis of EPTB, as recommended by the
World Health Organization (WHO) [3], is not easy. Diagnosis in
many low income countries is often based on presumptive and
circumstantial evidence, with the consequence of a possible
misdiagnosis [4].
In Be´nin, information is limited about this type of TB, especially
with regard to epidemiological characteristics and the most
predominant forms of EPTB. Furthermore, the treatment
outcomes of patients with EPTB are analyzed in the routine
programme together with those of patients with smear-negative
pulmonary tuberculosis, the latter in a recent study showing higher
rates of unsuccessful treatment compared with new smear-positive
pulmonary tuberculosis (NPTB) [5]. These treatment outcomes
are usually reported quarterly, using standard classifications; and a
‘‘treatment completion’’ is considered a successful outcome [3].
However, treatment can be completed without improvement of
the patient’s health condition, particularly if the diagnosis of EPTB
is wrong. The disappearance of initial symptoms along with weight
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gain in patients who have completed treatment might be a better
gauge of successful treatment.
In this study, we aimed to describe the pattern of disease in
patients registered as EPTB, their treatment outcomes and
among those who completed their treatment in the Centre
National Hospitalier de Pneumo-Phtisiologie (CNHP-P), the
proportion whose weight increased during the course of
treatment. Specific objectives were to determine in Be´nin for
2011: i) the number (and proportion) of patients recorded as
EPTB and NPTB among all TB cases, ii) demographic, clinical
characteristics and HIV-status of patients with EPTB and NPTB,
iii) treatment outcomes of patients with EPTB and NPTB and
the influence of HIV-infection and antiretroviral therapy and iv)
the proportion who increased in weight among those who
completed their treatment in the CNHP-P.
Materials and Methods
Ethics Statements
This study was approved by ‘‘Ethics Advisory Group’’ of the
International Union against Tuberculosis and Lung Disease, Paris,
France and ‘‘Be´nin TB Control Programme Coordination’’.
Because of its retrospective nature, the local Ethics Committee
approval (‘‘Comite´ National d’Ethique pour la Recherche en
Sante´’’) was not required according to the country’s recommen-
dations.
This study uses already collected data, and written informed
consent -given by participants was not possible to obtain. Patient
records/Information was collected anonymously. Each participant
of this study was attributed a unique identifier number, in order to
compare data files that have been double entered. After checking
and cleaning the database, the unique identifier numbers have
been removed and participants were de-identified prior to analysis.
There was no way to recognize them. All databases were kept
confidential and have been protected with a password, with only
access by authorized persons.
Study Design
This was a retrospective cohort study of all patients recorded as
EPTB and NPTB between 1st January and 31st December 2011 in
Be´nin.
Setting – General and Study Site, Including TB
Programme
Be´nin is a West-African country with a population of 9 million
and a HIV prevalence rate of 1.1% [6]. Seven to 10% of the 4000
TB patients registered each year have EPTB. There is a national
TB Programme which follows the DOTS strategy and uses
recognised international criteria for the diagnosis and treatment of
TB patients [7]. Diagnosis, registration and care are decentralised
to 57 Basic Management Units in the country. Of them, the largest
is the CNHP-P of Cotonou, the economic capital. It houses the
Mycobacteria Reference Laboratory where culture and molecular
diagnostics can be performed for the whole the country.
Diagnosis and management of NPTB and EPTB in the
Be´nin TB control Programme. Pulmonary TB diagnosis is
made with respect of WHO recommandations [2]. A person who
coughs more than 3 weeks is regarded as having presumptive
pulmonary tuberculosis. He/she is requested to provide two
sputum samples for acid-fast bacilli microscopy. Sputum samples
are examined using either auramine-phenol staining and fluores-
cence microscopy or Ziehl-Neelsen staining with light microscopy.
Patients with at least one sputum smear positive for acid-fast bacilli
and who have never been previously treated for TB (or less than
one month) are registered as NPTB.
A patient is considered as having presumptive EPTB if he/she
has symptoms suggestive of TB related to an extrapulmonary site,
with a decision then made by a medical doctor to treat with a full
course of anti-tuberculosis treatment. Usually, because of difficul-
ties in accessing and obtaining specimens from different biological
sites, TB treatment is started based on symptoms and other
circumstantial evidence that includes laboratory investigations and
radiographic abnormalities. Whenever possible, specimens col-
lected should be submitted for bacteriological investigation (direct
microscopy examination or standard culture, or molecular tests).
Rarely, these specimens are also analysed in histology laboratories.
In terms of registration, for patients who have TB in both
pulmonary and extrapulmonary sites, they are classified as having
‘‘pulmonary TB’’. For patients with TB in several extrapulmonary
sites (e.g., lymph nodes and pleural effusion), they are registered
according to the most severe form of disease.
All NPTB and EPTB cases are treated with the same
standardized first-line anti-tuberculosis regimen. Patients receive
daily rifampicin, pyrazinamide, isoniazid and ethambutol for 2
months (initial phase) followed by daily rifampicin and isoniazid
for 4 months (continuation phase). Contrary to the treatment of
NPTB, EPTB treatment is not directly observed during the
intensive phase and anti-tuberculosis drugs are given every two
weeks for self administration. Treatment is free and is only
provided by the Programme for all TB patients. TB drugs are not
available in private pharmacies in the city or country. While
sputum microscopy examination is performed during follow-up of
NPTB patients, those with EPTB are monitored clinically and in
particular body weight is measured and recorded during treatment
on personal treatment cards (at two, five and six months).
Standardized treatment outcomes are monitored through the
use of treatment cards and registers, and number of cases and
outcomes are quarterly reported.
TB/HIV co-infection management. Every patient who is
diagnosed with TB (including EPTB) is systematically offered an
HIV test using rapid tests and following national guidelines [8].
Those who are found to be HIV positive receive in addition
cotrimoxazole. Since 2011 and according to recent WHO
guidelines, all TB cases (including EPTB) are eligible for
antiretroviral therapy (ART) [9]. The first line ART regimen is
efavirenz and two other drugs, zidovudine and lamivudine. If
there is anemia (Haemoglobin,7 g/dl) or a low platelet count (,
75000/l) zidovudine is replaced by stavudine. Cotrimoxazole and
ART are provided free of charge.
Study Patients
All patients recorded as EPTB and NPTB between 1st January
and 31st December 2011 in Be´nin were included in the study.
Data Variables, Sources of Data and Data Collection
Variables for NPTB and EPTB patients included: sex, age,
residence by region, HIV-status (positive, negative, unknown),
cotrimoxazole and ART administration, treatment outcomes
(completion, death, loss-to-follow-up, not evaluated). Variables
for EPTB patients included in addition:- sites of disease (pleural
effusion, spinal, lymph node, bone or joint, ascites, other and not
recorded) and weight change during treatment for patients
managed in the CNHP-P. Individual data for EPTB patients
were collected from TB registers, laboratory TB registers,
treatment cards and TB medical personal files into a standardized
paper-based study questionnaire. For NPTB patients, data were
collected from quarterly and annual reports.
Extrapulmonary Tuberculosis in Be´nin
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Analysis and Statistics
Data were double entered into an electronic file (EpiData3.1,
EpiData Association, Odense, Denmark). Data were analyzed by
frequencies and percentages. Comparisons were made between
groups using the chi-square test, odds ratios (OR) and 95%
confidence intervals (95% CI) as appropriate. Levels of signifi-
cance were set at 5%.
Results
Numbers, Epidemiological and Diagnostic Characteristics
of TB Patients
The number and proportion of patients with EPTB and NPTB
diagnosed in the same time period are shown in Table 1. Overall,
EPTB patients represented 9% of all TB cases (mean age: 34.5
years, male/female ratio: 1.3), with a large variation between
regions from 23% in Borgou (North of the country) to 5% in
Oue´me´ (South of the country). All patients were new cases.
Demographic characteristics and HIV-status of patients with
EPTB and NPTB are shown in Table 2. There were significantly
more females (p = 0.001), children under 15 years (p,0.001) and
HIV-positive patients (p = 0.005) diagnosed with EPTB compared
with NPTB.
The different sites of EPTB are presented in Table 3. Pleural
effusion, spinal disease and lymph node disease accounted for 66%
of all EPTB cases. Demographic characteristics and HIV-status in
relation to the different sites of EPTB are shown in Table 4.
There was no association between gender and different types of
EPTB. Children (under 15 years) represented 16% (62/383) of all
EPTB cases diagnosed. Lymph node TB was more common in
children than adults (p,0.001) while TB pleural effusion was more
common in adults (p,0.001). Otherwise, there were no significant
associations between age and other sites of EPTB. Compared with
other regions, there was significantly more lymph node TB (OR:
2.6, 95%CI: 1.4–4.7, p = 0.001) and bone or joint TB (OR: 4.9,
95%CI: 2.1–11.6, p,0.001) in Zou while there was significantly
more TB pleural effusion in the Atlantique region. TB pleural
effusion was significantly more common in HIV-positive patients
compared with HIV-negative patients (p,0.001).
The only health facility where confirmation of diagnostic has
been assessed was CNHP-P. Of 130 EPTB patients registered and
followed-up in this centre, the diagnosis was confirmed for 9 cases
(7%): 2 with positive Mycobacterium tuberculosis culture and direct
smear examination, 1 with positive culture alone, 1 with positive
direct smear examination alone and 5 with histology showing
tuberculous granuloma. For aspirates of pleural or peritoneal fluid,
measurements of protein concentration and cytological analysis
were performed for all cases.
Treatment Outcomes
Treatment outcomes of patients with EPTB and NPTB are
presented in Table 5. Overall, 86% of patients successfully
completed treatment. There were significantly more patients with
EPTB who were lost-to-follow-up compared with NPTB (p,
0.001). Treatment outcomes in relation to demographic charac-
teristics, sites of disease, HIV-status and ART administration to
co-infected patients are shown in Table 6. No association was
found between gender and treatment outcomes. However,
treatment success was higher in children aged ,15 years (OR:
3.5, 95%CI: 1.0–14.8, p: 0.02). All patients who were lost-to-
follow-up during treatment were from the Atlantique region and
patients with pleural effusion or ascites had the worst completion
rates.
Finally, of 72 HIV-TB co-infected patients, 99% received
cotrimoxazole and 88% were given ART. HIV-positive patients
were at higher risk of death than HIV-negative patients during
treatment (OR: 2.5, 95%CI: 1.0–5.7, p: 0.02). In HIV-positive
patients, those on ART had much better outcomes than those not
on ART (82.5% versus 44.4%, p= 0.03). The concomitant
administration of ART was also associated with a lower loss-to-
follow-up rate (OR: 31, 95%CI: 2.2–922, p: 0.005). There were no
other significant differences.
Weight Variation during Treatment
The change in body weight among patients who completed
their treatment in relation to HIV-status in the CNHP-P, the
largest basic management unit in Be´nin, is shown in Table 7. Up
to 80% of patients who successfully completed treatment showed
an increase in body weight, and this was more apparent among
HIV-positive than HIV-negative patients (p = 0.03).
Discussion
This is the first study in Be´nin to describe the epidemiological
and diagnostic characteristics and treatment outcomes of EPTB
patients. Patients with EPTB constituted less than 10% of all
notifications, with some parts of the country showing higher
prevalence than others. EPTB appeared to be more common in
females, children under the age of 15 years and in those who were
HIV-positive. Predominant sites of disease were pleural, spinal and
Table 1. Patients with extrapulmonary tuberculosis and new smear-positive pulmonary tuberculosis registered in Be´nin and the
different regions of the country in 2011.
Place All TB** EPTB (%*) NPTB (%)
Be´nin 4320 383 (8.9) 3331 (77.1)
Regions Atacora 251 18 (7.2) 189 (75.3)
Borgou 367 58 (23.1) 255 (69.5)
Zou 567 70 (12.3) 442 (78)
Atlantique 1646 146 (8.9) 1226 (74.5)
Mono 664 51 (7.7) 534 (80.4)
Oue´me´ 825 40 (4.8) 685 (83)
Note: EPTB: Extrapulmonary tuberculosis; NPTB: New smear-positive pulmonary tuberculosis; TB: Tuberculosis.
* The percentage is calculated from the total number of TB cases diagnosed in each region.
** All TB cases include all patients with new and retreatment TB, irrespective of the site of tuberculosis.
doi:10.1371/journal.pone.0095603.t001
Extrapulmonary Tuberculosis in Be´nin
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lymph node, with TB lymph node disease being more common in
children and pleural effusion being more common in adults,
especially those HIV-positive. Diagnostic confirmation was rare
even in the largest basic management unit in the country.
Successful treatment completion was good especially in
children, although there was a higher rate of loss-to-follow-up
when compared with patients who had NPTB. Interestingly, all
patients lost to follow-up were from a specific region of Be´nin.
Patients with pleural effusion and ascites had the worst treatment
completion rates. Patients with HIV-associated TB remained at
higher risk of death compared with those who did not have HIV-
infection, although those on ART fared much better. Finally, in
CNHP-P where weight during the treatment has been collected,
there was a significant weight gain amongst those who completed
treatment, with the change in weight being more evident in
patients who were HIV-positive compared with those who were
not HIV-infected.
The strengths of this study were that it involved the whole
population and it was therefore nationally representative of the
epidemiology of EPTB in Be´nin. There was no need for any
sampling framework. In addition, basic management units are
regularly supervised every three months by the TB control
Programme coordination, and during these supervisory visits,
quarterly reports and patients’ personal data are systematically
reviewed and if necessary, corrections are made. Limitations
related to the operational nature of the study which used already
collected data from registers, medical files and quarterly reports
which are difficult to validate when conducting a retrospective
record review. In spite of regular supervision, some errors could
also remain in the consulted documents.
There were important variations in the proportion of EPTB
patients in the different regions of the country; and this could be
related to the implication of medical doctors in the diagnosis of this
form of TB. In Borgou region, where the highest proportion of
EPTB cases was reported from, the large majority of these patients
were diagnosed in two well frequented hospitals because of their
good reputation (a confessional centre and a teaching hospital).
The proportion of patients diagnosed with EPTB in Be´nin was
lower than that reported from other parts of world [1,10–15], and
few diagnoses were confirmed. Lack of appropriate and specific
diagnosis in EPTB in sub-Saharan Africa remains a continuing
source of debate [4]. There are recommendations that the
diagnosis of EPTB should be based on at least one specimen with
confirmed Mycobacterium tuberculosis (using microscopy examination,
culture or rapid molecular testing), histological or strong clinical
evidence consistent with active EPTB, followed by a clinician
decision to treat with a full course of tuberculosis chemotherapy
[3].
However, in resource-poor countries like Be´nin, following these
recommendations is difficult. Obtaining the diagnosis is difficult
for several reasons, such as lack of specialised physicians,
microbiologists and pathologists, weak laboratory infrastructure
and poor access to radiography and other more sophisticated
imaging technologies such as ultrasound and computerised
tomography scans.
The finding of females, children and HIV-positive patients
having a higher prevalence of EPTB is in line with reports from
other countries [1,12,16,17]. For children, the predominant site of
TB reported in the literature is usually lymph node disease [1],
although in adults a wide variety of patterns is reported from other
countries which may depend to a large extent on resources
Table 2. Demographic characteristics and HIV-status in patients with extrapulmonary tuberculosis and new smear-positive
pulmonary tuberculosis, Be´nin, 2011.
Characteristics EPTB (%) NPTB (%) p(value)
Sex Male 216 (56.4) 2158 (64.8) 0.001
Female 167 (43.6) 1173 (35.2) 0.001
Age (years) 00–14 62 (16.2) 62 (1.9) ,0.001
15–24 62 (16.2) 608 (18.3) NS
25–34 75 (19.6) 1035 (31.1) ,0.001
35–44 64 (16.7) 743 (22.3) 0.01
45–54 58 (15.1) 472 (14.2) NS
55–64 36 (9.4) 252 (7.6) NS
$65 26 (6.8) 159 (4.8) NS
HIV-status Positive 72 (18.8) 449 (13.5) 0.005
Negative or unknown 312 (81.5) 2882 (86.5) 0.005
Total 383 3331
Note: EPTB: Extrapulmonary tuberculosis, NPTB: New smear positive pulmonary tuberculosis; TB: Tuberculosis.
doi:10.1371/journal.pone.0095603.t002
Table 3. Different sites of extrapulmonary tuberculosis in
Be´nin, 2011.
Sites n (%)
Pleural effusion 94 (24.5)
Spine 82 (21.4)
Lymph node 77 (20.1)
Bone and Joint 29 (7.6)
Ascites 15 (3.9)
Other * 17 (4.4)
Not recorded 69 (18)
Total 383
Note: * Others include pericardial TB (n = 10), cerebral TB (n = 1), meningeal TB
(n = 1), female genital TB (n = 1), male genital TB (n = 3), skin TB (n = 1).
TB: Tuberculosis.
doi:10.1371/journal.pone.0095603.t003
Extrapulmonary Tuberculosis in Be´nin
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available for diagnosis [16,18–25]. In Be´nin, we found few patients
with TB meningitis, while the proportion diagnosed in others
studies has been higher [23,24]. This may be due to good coverage
of BCG immunization in Be´nin and also the difficulties in
establishing the diagnosis in this type of disease [22,26,27].
Although successful treatment completion was reasonable, this
could be improved by reducing the losses-to-follow-up, especially
in Atlantique region, where Cotonou, the economic capital city of
the country, is located. One of the reasons for patients being lost-
to-follow-up may be misdiagnosis, and this has been found in other
parts of Africa. Patients with other pathology such as lung cancer,
mesothelioma or systemic disease may be wrongly treated with
anti-tuberculosis drugs without improvement, persuading them to
seek alternative opinions and stopping treatment. Another reason
is that some patients reported as lost-to-follow-up may have died,
and this has also been found in other studies [28]. Finally more
attention needs to be paid to accurate diagnosis of patients with
pleural effusion and ascites, the latter especially having a wide
differential diagnosis that includes chronic liver disease.
Table 5. Treatment outcomes of patients with extrapulmonary tuberculosis and new smear-positive pulmonary tuberculosis in
Be´nin, 2011.
Treatment outcomes EPTB (%) NPTB (%) p (value)
Successful completion 331 (86.4) 2988 (89.9) ** 0.03
Failure 0 (0) 99 (3) ,001
Death 32 (8.4) 196 (5.9) NS
Loss-to-follow up 15 (3.9) 27 (0.9) ,0.001
Not evaluated 5 (1.3) 14 (0.4) 0.04
Total evaluated 383 3324 *
Note: EPTB: Extrapulmonary tuberculosis; NPTB: New smear positive pulmonary tuberculosis.
* 7 patients of the 3331 were wrongly registered as new smear-positive TB and were removed from the cohort analysis one year later.
** 2800 of the 2988 patients were cured with negative sputum smear examination for acid-fast bacilli.
doi:10.1371/journal.pone.0095603.t005
Table 6. Treatment outcomes of patients with extrapulmonary tuberculosis in relation to demographic characteristics, regions,
HIV status and ART administration in those with HIV coinfection, Be´nin, 2011.
Characteristics Total Completion Death Loss-to-follow-up Not evaluated
Sex Male 216 183 (84.7) 17 (7.9) 11 (5.1) 5 (2.3)
Female 167 148 (88.6) 15 (9) 4 (2.4) 0 (0)
Age (years) ,15 62 59 (95.2) 2 (3.2) 1 (1.6) 0 (0)
$15 321 272 (84.7) 30 (9.3) 14 (4.4) 5 (1.6)
Region Atacora 18 17 (94.4) 1 (5.6) 0 (0) 0
Borgou 58 47 (81) 10 (17.2) 0 (0) 1 (1.7)
Zou 70 67 (95.7) 2 (2.9) 0 (0) 1 (1.4)
Mono 51 47 (92.2) 4 (7.8) 0 (0) 0 (0)
Atlantique 146 114 (78.1) 14 (9.6) 15 (10.3) 3 (2.1)
Oue´me´ 40 39 (97.5) 1 (2.5) 0 (0) 0 (0)
Site Pleurisy 94 73 (77.7) 11 (11.7) 7 (7.4) 3 (3.2)
Spine 82 75 (91.5) 4 (4.9) 1 (1.2) 2 (2.4)
Lymph node 77 70 (90.9) 4 (5.2) 3 (3.9) 0 (0)
Bone and Joints 29 27 (93.1) 2 (6.9) 0 (0) 0 (0)
Ascites 15 10 (66.7) 4 (26.7) 1 (6.7) 0 (0)
Other* 17 14 (82.4) 1 (5.9) 2 (11.8) 0 (0)
Not recorded 69 62 (89.9) 6 (8.7) 1 (1.4) 0 (0)
HIV-Status Negative 306 270 (88.2) 21 (6.9) 11 (3.6) 4 (1.3)
HIV positive on ART 63 52 (82.5) 9 (14.3) 1 (1.6) 1 (1.6)
HIV positive not on ART 9 4 (44.4) 2 (22.2) 3 (33.3) 0 (0)
Unknown 5 5 (100) 0 (0) 0 (0) 0 (0)
Total 383 331 32 15 5
Note: * Others include pericardial TB (n = 10), cerebral TB (n = 1), meningeal TB (n = 1), female genital track TB (n = 1), male genital track TB (n = 3), skin TB (n = 1).
TB: Tuberculosis; ART: Antiretroviral therapy.
doi:10.1371/journal.pone.0095603.t006
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HIV-positive patients with EPTB were at higher risk of death
than HIV-negative patients, despite good coverage with ART.
Often, HIV-infected patients with EPTB present with advanced
immune suppression with CD4 counts ,200 cells/ml, and hence
their classification as a WHO Stage 4 AIDS defining disease. As a
result, patients can also be affected by other opportunistic diseases
that can result in death [29,30]. The time of start of ART in
relation to start of anti-TB treatment is an important factor that
determines mortality, and late initiation of ART is associated with
increased case fatality [9]. A weakness of this study was the lack of
information about when ART was started.
Finally, we assessed whether patients who completed treatment
increased their weight, the latter adding to the evidence to support
a successful treatment completion. The large majority of patients
who completed their treatment showed an increase in body
weight, especially in HIV-positive patients, and this has been
found elsewhere. As recommended in guidelines, weight should be
regularly measured during the course of treatment [4,31].
The findings of this study have several implications for the
Be´nin TB control Programme. First, there is a need to improve the
diagnosis of EPTB in the country and to perform appropriate
examinations when needed such as mycobacterial culture on tissue
and other specimens. The introduction of rapid molecular tests
such as Xpert MTB/RIF should be considered especially for the
more difficult-to-diagnose cases of EPTB [32,33]. Second, the
follow-up of patients during treatment must improve especially in
the Atlantique region where there was high loss-to-follow-up.
Third, more attention needs to be paid to getting HIV-infected
patients on to ART as soon as possible and to ensure that the time
of start of ART in relation to start of anti-TB treatment is well
documented.
Conclusion
The study has shown that the proportion of patients diagnosed
and registered with EPTB was low and below 10%. Treatment
outcomes of EPTB cases were satisfactory, although the high loss-
to-follow-up in the Atlantique region of the country needs to be
rectified. The TB control Programme in Be´nin would benefit
through more attention to accurate diagnosis of EPTB and earlier
start of ART in HIV-infected patients.
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